Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Net Income (2016 - 2025)

Regenxbio (RGNX) has 12 years of Net Income data on record, last reported at -$67.2 million in Q4 2025.

  • For Q4 2025, Net Income fell 31.01% year-over-year to -$67.2 million; the TTM value through Dec 2025 reached -$194.0 million, up 14.66%, while the annual FY2025 figure was -$194.0 million, 242351.25% down from the prior year.
  • Net Income reached -$67.2 million in Q4 2025 per RGNX's latest filing, down from -$62.0 million in the prior quarter.
  • Across five years, Net Income topped out at $294.1 million in Q4 2021 and bottomed at -$76.7 million in Q1 2022.
  • Average Net Income over 5 years is -$41.9 million, with a median of -$61.9 million recorded in 2023.
  • The widest YoY moves for Net Income: up 735.97% in 2021, down 764.37% in 2021.
  • A 5-year view of Net Income shows it stood at $294.1 million in 2021, then tumbled by 120.36% to -$59.9 million in 2022, then dropped by 5.17% to -$63.0 million in 2023, then grew by 18.58% to -$51.3 million in 2024, then plummeted by 31.01% to -$67.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$67.2 million in Q4 2025, -$62.0 million in Q3 2025, and -$70.9 million in Q2 2025.